As long as we are on the OTC the market dictates w
Post# of 30025
I don't believe their methodology is superior to MANF in the least. It is too invasive.
http://neuroderm.com/about-neuroderm/
(" ** NEURODERM LTD, $15.03, +10.11 pct
Brokerage Oppenheimer raised its price target to $19 from $18 on the drug developer's stock to reflect higher chances of the company's Parkinson's disease drug being successful in later studies. NeuroDerm on Dec. 30 announced positive mid-stage study data of the drug.)
This is what an uplist can accomplish...this stock is up 12.59% as we speak on mediocre news, the same type of news we've seen AMBS put out routinely but failed to impress "the markets "...
http://ir.neuroderm.com/phoenix.zhtml?c=25374...sharechart
Given time and an uplist, Amarantus will impress all longs imho...